C. Cheah

发表

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.

M. Shadman, L. Nastoupil, S. Assouline, 2024, Journal of Clinical Oncology.

Mantle Cell Lymphoma

S. Pileri, P. M. Banks, R. Warnke, 2022, The EBMT/EHA CAR-T Cell Handbook.

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

I. Flinn, N. Bartlett, C. Cheah, 2020 .

Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

A. Ruppert, K. Izutsu, W. Wierda, 2023, Blood.

Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter's Transformation

N. Bartlett, S. Assouline, D. El-Sharkawi, 2023, Blood.

Australia and New Zealand consensus position statement: use of COVID‐19 therapeutics in patients with haematological malignancies

A. Enjeti, R. Weinkove, M. Latimer, 2023, Internal medicine journal.

Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.

L. Sehn, J. Connors, K. Savage, 2018, European journal of cancer.

Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project

K. Manos, Jock D Simpson, N. Viiala, 2024, EJHaem.